Delayed Initial Radioiodine Adjuvant Therapy Does Affect Biochemical Response in Intermediate- to High-Risk Differentiated Thyroid Cancer

被引:8
|
作者
Yu, Feng [1 ]
Li, Xue [1 ]
Ji, Yanhui [1 ]
Tan, Jian [1 ]
Zhang, Guizhi [1 ]
Wang, Peng [1 ]
He, Yajing [1 ]
Wang, Renfei [1 ,2 ]
机构
[1] Tianjin Med Univ Gen Hosp, Dept Nucl Med, Tianjin, Peoples R China
[2] Shanghai Jiao Tong Univ Affiliated Peoples Hosp 6, Dept Nucl Med, Shanghai, Peoples R China
来源
关键词
Differentiated thyroid carcinoma (DTC); Radioiodine therapy; timing; therapy response; prognosis; RADIOACTIVE IODINE THERAPY; REMNANT ABLATION; SURVIVAL; THYROGLOBULIN; RECURRENCE; CARCINOMA; OUTCOMES; NODULES; IMPACT;
D O I
10.3389/fendo.2021.743310
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundThere are no definite recommendations on the optimal time of initiating radioactive iodine (RAI) therapy for differentiated thyroid cancer (DTC) patients in current relevant guidelines. This study aimed to investigate the relationship between the timing of initiating radioiodine adjuvant therapy (RAT) and the clinical outcomes based on dynamic follow-ups and assessments in intermediate- to high-risk DTC patients. MethodsA total of 206 patients with intermediate- to high-risk DTC receiving RAT of 150 mCi were retrospectively reviewed. According to the time interval (TI: between thyroidectomy and initial RAT), the patients were divided into 2 groups: Group 1: TI < 3 months (n=148), and Group 2: TI >= 3 months (n=58). The RAT therapy response was evaluated as excellent response (ER), indeterminate response (IDR), biochemical incomplete response (BIR), structural incomplete response (SIR). The univariate and multivariate analyses were conducted to screen out factors associated with incomplete response (IR= BIR+SIR). Finally, the prognostic nomogram was used to explain IR rates as a valuable tool in clinical practice. ResultsResponse to initial RAT was significantly different between 2 groups during dynamic follow-ups (all P<0.05). Group 2 had significantly lower ER rates (37.9 vs 63.5, 52.0 vs 73.9, 64.4 vs 80.3, all P<0.05, respectively) and higher IR rates (39.7 vs 14.9, 36.0 vs 9.7, 12.2 vs 3.9, all P<0.05, respectively) than group 1 during dynamic follow-ups. By univariate and multivariate analyses, prolonged TI (HR: 6.67, 95%CI: 2.241-19.857, P=0.001), soft tissue invasion (HR: 7.35, 95%CI: 1.624-33.296, P=0.010), higher sTg (HR: 7.21, 95%CI: 1.991-26.075, P=0.003) were manifested to be independent risk factors for IR. The nomogram showed that soft tissue invasion, sTg, and TI were the top 3 contributors to the IR. ConclusionsEarly RAT is associated with greater biochemical response but has no impact on SIR. Delayed initial RAT (>= 3 months after thyroidectomy) related to IR in intermediate- to high-risk DTC.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Low-dose radioiodine therapy for patients with intermediate- to high-risk differentiated thyroid cancer
    Abe, Koichiro
    Ishizaki, Umiko
    Ono, Toshihiro
    Horiuchi, Kiyomi
    Kanaya, Kazuko
    Sakai, Shuji
    Okamoto, Takahiro
    [J]. ANNALS OF NUCLEAR MEDICINE, 2020, 34 (02) : 144 - 151
  • [2] Low-dose radioiodine therapy for patients with intermediate- to high-risk differentiated thyroid cancer
    Koichiro Abe
    Umiko Ishizaki
    Toshihiro Ono
    Kiyomi Horiuchi
    Kazuko Kanaya
    Shuji Sakai
    Takahiro Okamoto
    [J]. Annals of Nuclear Medicine, 2020, 34 : 144 - 151
  • [3] Impact of delayed radioiodine therapy in intermediate-/high-risk papillary thyroid carcinoma
    Kim, Mijin
    Han, Minkyu
    Jeon, Min Ji
    Kim, Won Gu
    Kim, In Joo
    Ryu, Jin-Sook
    Min, Won Bae
    Shong, Young Kee
    Kim, Tae Yong
    Kim, Bo Hyun
    [J]. CLINICAL ENDOCRINOLOGY, 2019, 91 (03) : 449 - 455
  • [4] Incomplete response to therapy in intermediate- and high-risk thyroid cancer
    Ali S. Alzahrani
    Noha Mukhtar
    [J]. Endocrine, 2022, 78 : 531 - 542
  • [5] Incomplete response to therapy in intermediate- and high-risk thyroid cancer
    Alzahrani, Ali S.
    Mukhtar, Noha
    [J]. ENDOCRINE, 2022, 78 (03) : 531 - 542
  • [6] Delayed initial radioiodine therapy related to incomplete response in low- to intermediate-risk differentiated thyroid cancer
    Li, Hui
    Zhang, Ying-qiang
    Wang, Chen
    Zhang, Xin
    Li, Xin
    Lin, Yan-song
    [J]. CLINICAL ENDOCRINOLOGY, 2018, 88 (04) : 601 - 606
  • [7] Comparison of thyroid hormone withdrawal and recombinant human thyroid-stimulating hormone administration for adjuvant therapy in patients with intermediate- to high-risk differentiated thyroid cancer
    Iizuka, Yusuke
    Katagiri, Tomohiro
    Ogura, Kengo
    Inoue, Minoru
    Nakamura, Kiyonao
    Mizowaki, Takashi
    [J]. ANNALS OF NUCLEAR MEDICINE, 2020, 34 (10) : 736 - 741
  • [8] Comparison of thyroid hormone withdrawal and recombinant human thyroid-stimulating hormone administration for adjuvant therapy in patients with intermediate- to high-risk differentiated thyroid cancer
    Yusuke Iizuka
    Tomohiro Katagiri
    Kengo Ogura
    Minoru Inoue
    Kiyonao Nakamura
    Takashi Mizowaki
    [J]. Annals of Nuclear Medicine, 2020, 34 : 736 - 741
  • [9] Post-operative radioiodine therapy (RaIT) as adjuvant therapy in low–intermediate risk differentiated thyroid cancer
    Alfredo Campennì
    Salvatore Antonio Pignata
    Sergio Baldari
    [J]. Clinical and Translational Imaging, 2018, 6 : 347 - 355
  • [10] Predictive value of FDG PET at initial radioiodine therapy for survival of high-risk patients with differentiated thyroid cancer
    Gaertner, Florian
    Okamoto, Shozo
    Shiga, Tohru
    Ito, Yoichi
    Uchiyama, Yuko
    Manabe, Osamu
    Hattori, Naoya
    Tamaki, Nagara
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2014, 55